Xilio Therapeutics, Inc. (XLO) Stock Price & Analysis
Xilio Therapeutics, Inc. (XLO) rose 2.66% to USD 7.9 as of June 10, 2026 at 00:46 UTC, according to Nexqual real-time market data.
XLO last closed at USD 7.7; the session ranged USD 7.57–7.93 on volume of 36,395 shares. Market capitalization is $51.94M, with a 52-week range of USD 6.47–12.74 (NCM). Source: Nexqual, June 10, 2026 at 00:46 UTC.
Key Statistics (as of June 10, 2026 at 00:46 UTC)
| Price | USD 7.9 |
|---|---|
| Change | ▲ 2.66% (up) |
| Previous Close | USD 7.7 |
| Open | USD 7.62 |
| Day Range | USD 7.57 – 7.93 |
| 52-Week Range | USD 6.47 – 12.74 |
| Volume | 36,395 shares |
| Market Cap | $51.94M |
| Exchange | NCM |
Technical Analysis (XLO)
Nexqual's technical model rates XLO "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:46 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 42.77 (neutral) |
| vs SMA50 | Below (USD 8.25) |
| MACD | -0.07 (negative) |
Analyst Ratings (XLO)
Wall Street analysts rate XLO "None" based on 1 analysts, with a mean price target of USD 20 (range USD 20–20), per Nexqual as of June 10, 2026 at 00:46 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 20 |
| High Target | USD 20 |
| Low Target | USD 20 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (XLO)
| Revenue Estimate | $12.72M |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-09-30 | USD -1.54 vs est -0.42 ▼ miss |
| 2025-06-30 | USD -2.24 vs est -1.12 ▼ miss |
Source: Nexqual, June 10, 2026 at 00:46 UTC.
Financials & Fundamentals (XLO)
| Total Revenue | $53.48M |
|---|---|
| Revenue Growth (YoY) | +331.70% |
| Gross Margin | +100.00% |
| Operating Margin | -111.58% |
| Profit Margin | -58.52% |
| ROE | -75.20% |
| Debt / Equity | 9.15 |
| Current Ratio | 3.59 |
| Total Cash | $150.33M |
| Total Debt | $6.64M |
| Free Cash Flow | $-23.71M |
Source: Nexqual, June 10, 2026 at 00:46 UTC.
Financial Health Score (XLO)
Nexqual rates Xilio Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:46 UTC.
| Growth | Strong — Revenue +590% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $150M cash vs $7M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$24M, burning cash |
| Efficiency | Critical — ROE -75%, ROA -19.8% |
Ownership (XLO)
| Insider Ownership | +28.58% |
|---|---|
| Institutional Ownership | +53.54% |
| Shares Outstanding | 6.58M |
| Float | 3.65M |
| Short % of Float | +3.24% |
Source: Nexqual, June 10, 2026 at 00:46 UTC.
Leadership (XLO)
Xilio Therapeutics, Inc. is led by Rene Russo BCPS, Pharm.D. (age 50), President, CEO & Director, per Nexqual as of June 10, 2026 at 00:46 UTC.
| President, CEO & Director | Rene Russo BCPS, Pharm.D. (age 50) |
|---|---|
| CFO & COO | Christopher Frankenfield (age 43) |
| Senior Vice President of Finance & Accounting | Kevin M. Brennan (age 55) |
| Chief Scientific Officer | Uli Bialucha |
| Senior Vice President of Medical Affairs | Ruth du Moulin |
Major Backers & Investors (XLO)
Notable institutional backers of Xilio Therapeutics, Inc. include Bain Capital Life Sciences Investors, LLC, Gilead Sciences Inc, Frazier Life Sciences Management, L.P. , according to Nexqual as of June 10, 2026 at 00:46 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Bain Capital Life Sciences Investors, LLC | 10.1% |
| Gilead Sciences Inc | 9.89% |
| Frazier Life Sciences Management, L.P. | 6.43% |
| Sio Capital Management, LLC | 2.32% |
| Caligan Partners, LP | 1.71% |
| Merck & Co., Inc. | 1.61% |
| Stonepine Capital Management, LLC | 0.98% |
| Morgan Stanley | 0.87% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.77% |
Source: Nexqual, June 10, 2026 at 00:46 UTC.
From Xilio Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-23)
Key Strengths & Strategy (as disclosed to the SEC)
- Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies.
- The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RLYB | Rallybio Corporation | USD 15.91 | ▼ 0.25% |
| HOWL | Werewolf Therapeutics, Inc. | USD 0.37 | ▼ 4.46% |
| TYRA | Tyra Biosciences, Inc. | USD 25.94 | ▼ 2.63% |
| INAB | IN8bio, Inc. | USD 1.45 | ▲ 0% |
| IMRX | Immuneering Corporation | USD 4.03 | ▼ 5.62% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:46 UTC. This page is informational and not investment advice.